Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Apr 8, 2026 (6 months ago)

Revitaderm Wound Care Gel

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Microbial contamination of Non-Sterile Product: samples identified the presence of Lysinibacillus fusiformis and other Bacillus spp

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Revitaderm Wound Care Gel, Benzalkonium Chloride 0.1%, packaged in 1.0 FL OZ (37 mL) bottle, shorter twist cap, Manufactured By: Blaine Labs, Inc. 11037 Lockport Place Santa Fe Springs, CA 90670, NDC 63347-120-02.

Affected NDC 63347-0120-02

Compare with the code on your package — it is the most precise check available.

Drug: Benzalkonium

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
RevitaDERM Wound Care
Benzalkonium Chloride
NDC 63347-0120
170 mg/89mL Gel
Topical
Blaine Labs Inc. OTC
Recalling firm
Blaine Labs Inc
NDC code
63347-120-02
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0692-2026 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other Benzalkonium recalls

See all
Class II · Moderate risk

Revitaderm Wound Care

CGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminated

Ongoing cGMP deviation Blaine Labs Inc NDC 63347-120-02 D-0699-2026
Class II · Moderate risk

Dynarex

CGMP Deviations

Ongoing cGMP deviation Acme United Corporation NDC 67777-245-04 D-0376-2026

Other recalls by Blaine Labs Inc

All 2026 recalls
Class II · Moderate risk

Revitaderm Wound Care

CGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminated

Ongoing cGMP deviation Blaine Labs Inc NDC 63347-120-02 D-0699-2026
Class II · Moderate risk

vite20 Antifungal Cream

CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry

Ongoing Stability / shelf life Blaine Labs Inc D-0696-2026